Alkeus Pharmaceuticals Licenses Novel Ophthalmologic Therapies From Columbia University With Applications In Dry-AMD And Stargardt’s Disease
Alkeus Pharmaceuticals and Columbia University announced today that they have entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye. Left untreated, these conditions often lead to impaired vision and even blindness. Dr...